What does TB-500 cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [4] |
| Compounded pharmacy | Not published | No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient TB-500 under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous or intramuscular injection, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7] |
What is the list price of TB-500?
There is no list price: TB-500 is not an FDA approved drug. HHS's October 2026 draft policy covers conditional compounding of the single-ingredient product, but no dated price from a qualifying pharmacy has been verified yet. Products sold as research chemicals for human use are unapproved drugs and are not a comparable price.
Does insurance cover TB-500?
Not covered by commercial plans or Medicare because it is an unapproved compounded product.
What changes the price?
- HHS's October 2026 draft policy covers only single-ingredient compounding under conditions (patient-specific prescription, allowed route, tested substance from an FDA-registered manufacturer); blends are excluded and no qualifying pharmacy price has been verified yet
Frequently asked questions
How much does TB-500 cost without insurance?
No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient TB-500 under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous or intramuscular injection, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7]
Does insurance cover TB-500?
Not covered by commercial plans or Medicare because it is an unapproved compounded product. [4]
What is the list price of TB-500?
There is no list price: TB-500 is not an FDA approved drug. HHS's October 2026 draft policy covers conditional compounding of the single-ingredient product, but no dated price from a qualifying pharmacy has been verified yet. Products sold as research chemicals for human use are unapproved drugs and are not a comparable price.
Related pages
- TB-500: evidence, legality, and access
- BPC-157 vs TB-500 (BPC-157 cost)
- TB-500 vs GHK-Cu (GHK-Cu cost)
- Thymosin alpha-1 vs TB-500 (Thymosin alpha-1 cost)
- Tendon injury and tendinopathy: peptide evidence
- Muscle recovery and injury: peptide evidence
- Wound healing: peptide evidence
- Traumatic brain injury: peptide evidence
- Osteoarthritis: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- TB-500 side effects and benefits: what the evidence shows
No human study of TB-500 has been published, so its side effects in people are unknown. What FDA's 2026 review found, which studies tested a different peptide, and its legal status.
- TB-500 vs thymosin beta-4: is it the same peptide?
FDA says TB-500 and thymosin beta-4 are not the same substance. What each one is, which one the human and animal studies used, capsules and sprays, and the cancer question.
Sources
- [1]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [4]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [6]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS notice of availability of a draft policy, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy; publication scheduled October 30, 2026)Federal Register, 2026
- [7]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026